Jens Holstein is recorded as CFO at BioNTech SE (BNTX). Jens Holstein was last confirmed as Board Member at Veracyte, Inc. (VCYT) in a filing dated April 25, 2024. Veracyte, Inc. reported in an 8-K filed June 11, 2026 that Jens Holstein was appointed director, effective June 10, 2026. Veracyte, Inc. reported in an 8-K filed June 18, 2025 that Jens Holstein was appointed director, effective June 17, 2025. Jens Holstein has spoken on 13 earnings calls across 1 company, most recently for BioNTech SE on March 31, 2025. BioNTech SE is classified in the Biotechnology industry within the Healthcare sector.
“Each of the nine nominees for director was elected to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified.”
Veracyte, Inc. Form 8-K, filed June 11, 2026
· Read the filing
“Each of the seven nominees for director was elected to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified.”
Veracyte, Inc. Form 8-K, filed June 18, 2025
· Read the filing
Jens Holstein on recent calls
“Let me begin my section with our Q1 2025 financial results. In the first quarter of 2025, we reported total revenues of approximately €183 million, driven mostly by the sale of our COVID-19 vaccines, compared with €188 million for the first quarter of 2024.”
“I'll start with our fourth quarter and full-year results for 2024. Then I'll share our 2025 financial guidance. In terms of our financial results, we executed the year according to our plans.”
“Let me start by reviewing our financial results for the three months ended September 30, 2024. The total revenues reported for the period were approximately €1.245 billion, mostly recorded in September, compared to approximately €895 million for the third quarter of 2023.”
“Let me start by reviewing our financial results for the three months ended June 30, 2024. Our total revenues reported for the second quarter of 2024 reached approximately €129 million compared with approximately €168 million for the second quarter of 2023.”
“A warm welcome to everyone who has dialed into today's call. Let me begin my section with some key financial figures for Q1 2024. In the first quarter of 2024, we reported total revenues of approximately EUR 188 million driven mostly by commercial revenues from the sales of our COVID-19 vaccine.”
